Journal
BLOOD
Volume 139, Issue 5, Pages 686-689Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021011386
Keywords
-
Categories
Funding
- Genentech/AbbVie
- Richter syndrome
- Clinical Research from the Leukemia & Lymphoma Society
Ask authors/readers for more resources
In this study, we found that the oral Bcl-2 inhibitor venetoclax could increase the sensitivity of Richter syndrome (RS) of chronic lymphocytic leukemia (CLL) to chemoimmunotherapy and improve treatment outcomes. In a single-arm trial, the combination of venetoclax and chemotherapy resulted in a 50% complete response rate, with deeper and more durable responses compared to historical regimens. Our data suggest that further studies comparing venetoclax with chemoimmunotherapy to chemoimmunotherapy alone are warranted.
Richter syndrome (RS) of chronic lymphocytic leukemia (CLL) is typically chemoresistant, with a poor prognosis. We hypothesized that the oral Bcl-2 inhibitor venetoclax could sensitize RS to chemoimmunotherapy and improve outcomes. We conducted a single-arm, investigator-sponsored, phase 2 trial of venetoclax plus dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (VR-EPOCH) to determine the rate of complete response (CR). Patients received R-EPOCH for 1 cycle, then after count recovery, accelerated daily venetoclax ramp-up to 400 mg, then VR-EPOCH for up to 5 more 21-day cycles. Responders received venetoclax maintenance or cellular therapy off-study. Twenty-six patients were treated, and 13 of 26 (50%) achieved CR, with 11 achieving undetectable bone marrow minimal residual disease for CLL. Three additional patients achieved partial response (overall response rate, 62%). Median progression-free survival was 10.1 months, and median overall survival was 19.6 months. Hematologic toxicity included grade >= 3 neutropenia (65%) and thrombocytopenia (50%), with febrile neutropenia in 38%. No patients experienced tumor lysis syndrome with daily venetoclax ramp-up. VR-EPOCH is active in RS, with deeper, more durable responses than historical regimens. Toxicities from intensive chemoimmunotherapy and venetoclax were observed. Our data suggest that studies comparing venetoclax with chemoimmunotherapy to chemoimmunotherapy alone are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available